Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that its cash and cash equivalents amounted to EUR 111.7 million (US$ 132.3 million) at December 31, 2005. This represents a net increase of EUR 35.0 million (US$ 41.4 million) over the cash and cash equivalents balance of EUR 76.7 million (US$ 90.8 million) at year-end 2004.
